

# Find clinical trials studying a particular drug in Cortellis

This guide explains how to identify clinical studies on a drug of interest in Cortellis.

The Cortellis editorial team attend global conferences and read through hundreds of press releases, clinical trial registry sites and other sources every day to provide you with insights from the industry. This information is gathered, indexed by experts and made available to you in Clinical Trial reports.

When looking for clinical trials studying a particular drug, Cortellis offers quick searches as well as filters to limit your results to trials including a specific endpoint, patient segment\*, biomarker or adverse event of interest.

**Example:** Find completed phase 2 trials studying nivolumab in patients with lung cancer and identify associated gene variants\*.

1. Run your search by brand or active ingredient name.



2. Select 'Clinical Trials'\* from Report Type menu on the left:

2088 results found for index Search for the search term 'nivolumab'		
Report Type	Results	Per page: 25   Sort by: Last Change Date   Most Recent
<ul style="list-style-type: none"> <li>Show selected only</li> <li>Broker Research (24500)</li> <li><b>Clinical Trials (2088)</b></li> <li>Companies (0)</li> <li>Conferences (1026)</li> <li>Deals (109)</li> <li>Disease Briefings (16)</li> <li>Drugs (17)</li> </ul>	<ul style="list-style-type: none"> <li>Title</li> <li> <a href="#">TOP2101: A Randomized, Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naive Patients With Metastatic NSCLC</a> </li> <li> <a href="#">A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and</a> </li> </ul>	<ul style="list-style-type: none"> <li>Condition</li> <li>Filters: [0]</li> <li>Metastatic non small cell lung cancer</li> <li>Adenocarcinoma; Metastatic esophageal cancer; Metastatic stomach cancer</li> </ul>

\*Depending on your type of subscription.

3. Apply filters to narrow down your results.

SHOW ALL FILTERS

Search Patient Segment  Look up

Non-Hierarchical List  
 Hierarchical List

Condition

**Patient Segment**

Biomarkers

Biomarker Type

Biomarker Role

Drug Pipeline Interventions

Drug Pipeline Highest Development Status

Site Name

- Lung tumor (385)
  - Others (4)
  - Subjects at risk of developing disease (3)
  - Subjects with Advanced/Metastatic Cancer (329)
  - Subjects with Early Stage Lung Cancer (25)
  - Subjects with EGFR Positive Lung Cancer (46)
  - Subjects with gene variants (58)**
    - AKT1\_HUMAN\_Mutation (1)
    - ALK\_HUMAN\_Fusion (2)
    - ALK\_HUMAN\_Mutation (14)
    - ALK\_HUMAN\_Mutation(GOF) (1)
    - ALK\_HUMAN\_Rearrangement (15)

Use hierarchical filters to include sub terms automatically.

Condition

Patient Segment

Biomarkers

Biomarker Type

Biomarker Role

Drug Pipeline Interventions

Drug Pipeline Highest Development Status

Site Name

Contact Name

Sponsors/Collaborators

Phase

**Recruitment Status**

Select All/Deselect All

- No longer recruiting (6)
- Completed (6)
- Recruiting (3)
- Terminated (2)
- Status not specified (1)

4. Next page displays your results. Options at the top right allow you to set up alerts, save and export your results. To find out more about a specific trial, click the title as shown next.

< Back | Forward > Search Results Related Content Analyze Save and Alert Download

4 results found for index Search for the search term 'nivolumab' with filter(s) applied: Subjects with gene variants; Phase 1/Phase 2 Clinical; Phase 2 Clinical; Completed; Yes

First Previous 1 Next Last

Report Type	Results	Per page: 25	Sort by: Phase	Highest to Lowest	Order Columns	View
<ul style="list-style-type: none"> <li>Broker Research (24500)</li> <li><b>Clinical Trials (2088)</b></li> <li>Companies (0)</li> <li>Conferences (1026)</li> <li>Deals (109)</li> </ul>	<input checked="" type="checkbox"/> Title					
	<input checked="" type="checkbox"/> <a href="#">Study of Efficacy and Safety of Nivolumab in Combination With EGFR-TKI and of Nivolumab in Combination With IHC-289 in Patients With Previously Treated Non-small Cell Lung Cancer</a>		Adenocarcinoma; Metastatic non small cell lung cancer	Lung tumor - Subjects with Advanced/Metastatic Cancer - Subjects with locally advanced/stage III lung cancer; Lung tumor - Subjects with Advanced/Metastatic Cancer - Subjects with metastatic/stage IV lung	Lung tumor - Assessment of Laboratory/Diagnostic Measures - Cardiac function tests; Lung tumor - Assessment of Objective Response - Assessment of objective response rate(ORR); Lung tumor - Assessment of	Completed

Conditions, enrolment data, mechanism of action and other details can be found in 'Snapshot' tab.

Study of Efficacy and Safety of Nivolumab in Combination With EGF-816 and of Nivolumab in Combination With INC-280 in Patients With Previously Treated Non-small Cell Lung Cancer	
<b>Snapshot</b>	Highlight <input type="checkbox"/> Search Terms & Synonyms < Previous Next >
Protocol & Results	SNAPSHOT Results Available <b>Yes</b> Endpoints Met <b>Unspecified</b>
Subjects & Measurements	Title Study of Efficacy and Safety of Nivolumab in Combination With EGF-816 and of Nivolumab in Combination With INC-280 in Patients With Previously Treated Non-small Cell Lung Cancer
Registry Contacts & Sites	Scientific Title A Phase II, Multicenter, Open-Label Study of EGF-816 in Combination With Nivolumab in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer and of INC-280 in Combination With Nivolumab in Adult Patients With cMet Positive Non-small Cell Lung Cancer
Change History	Identifiers NCT02323126; 2014-003731-20; CEGF816X2201C
Sources	Condition Adenocarcinoma; Metastatic non small cell lung cancer <a href="#">View Epidemiology in IPD</a>
	Disease Markers Epidermal growth factor receptor; Hepatocyte growth factor receptor;
	Primary Interventions Variable regimens including: <a href="#">capmatinib</a> , <a href="#">nazartinib</a> , <a href="#">nivolumab</a>

Results\*, adverse events\* and protocols -including trial arms- are available in the next tab.

Snapshot										
<b>Protocol &amp; Results</b>	Highlight <input type="checkbox"/> Search Terms & Synonyms < Previous Next >									
<ul style="list-style-type: none"> <li>Alms &amp; Scope</li> <li>Protocol Description</li> <li>Trial Arms</li> <li>Regimens</li> <li>Results</li> <li>Adverse Events</li> <li>Treatment</li> </ul>	<p><b>PROTOCOL &amp; RESULTS</b></p> <p><b>AIMS &amp; SCOPE</b></p> <p>The purpose of this study was to determine the efficacy and safety of <a href="#">nivolumab</a> in combination with <a href="#">EGF-816</a> and of nivolumab in combination with <a href="#">INC-280</a> in previously treated non small cell lung cancer (NSCLC) patients.</p> <p>The main objective of the trial was to estimate the clinical activity of nivolumab in combination with EGF-816 or INC-280.</p> <p>The secondary objectives of the trial were:            To evaluate the preliminary antitumor activity of EGF-816 and nivolumab and of INC-280 and nivolumab.            To characterize the safety and tolerability of EGF-816 and nivolumab or of INC-280 and nivolumab.            To evaluate PK of EGF-816, INC-280 and nivolumab in the combination setting.</p> <p><b>PROTOCOL DESCRIPTION TEXT</b></p> <p>Patients would receive 10 mg/1ml of nivolumab either with 25 mg of EGF-816 or 200 mg of INC-280 po.</p> <p>Arm 1 (EGF816 + nivolumab) would be currently closed to new enrollment.            Arm 2 (INC280 + nivolumab) would be open and enrolling as planned.</p> <p><b>TRIAL ARMS</b></p> <table border="1"> <thead> <tr> <th>Label</th> <th>Type</th> <th>Description</th> </tr> </thead> <tbody> <tr> <td>Nivolumab and INC280</td> <td>Experimental</td> <td>Arm 2 (INC280 + nivolumab) is open and enrolling as planned.</td> </tr> <tr> <td>Nivolumab and EGF816</td> <td>Experimental</td> <td>Arm 1 (EGF816 + nivolumab) is currently closed to new enrollment.</td> </tr> </tbody> </table>	Label	Type	Description	Nivolumab and INC280	Experimental	Arm 2 (INC280 + nivolumab) is open and enrolling as planned.	Nivolumab and EGF816	Experimental	Arm 1 (EGF816 + nivolumab) is currently closed to new enrollment.
Label	Type	Description								
Nivolumab and INC280	Experimental	Arm 2 (INC280 + nivolumab) is open and enrolling as planned.								
Nivolumab and EGF816	Experimental	Arm 1 (EGF816 + nivolumab) is currently closed to new enrollment.								
Subjects & Measurements										
Registry Contacts & Sites										
Change History										
Sources										

\*Depending on your type of subscription.

'Subjects and measurements' tab displays eligibility criteria, biomarkers, patient segmentation\* as well as primary and secondary endpoints\* included in this trial.

Snapshot	Highlight <input type="checkbox"/> Search Terms & Synonyms	< Previous	Next >
Protocol & Results	<b>SUBJECTS &amp; MEASUREMENTS</b>		
<b>Subjects &amp; Measurements</b>	<b>ELIGIBILITY CRITERIA</b>		
<ul style="list-style-type: none"> <li>■ Eligibility Criteria</li> <li>■ Outcome Measures</li> <li>■ <b>Patient Segmentation</b></li> <li>■ Biomarkers</li> </ul>	<b>PATIENT SEGMENTATION</b>		
Registry Contacts & Sites	<ul style="list-style-type: none"> <li>■ Lung tumor           <ul style="list-style-type: none"> <li>■ Subjects with Non Small Cell Lung Cancer (NSCLC)</li> <li>■ Subjects with Advanced/Metastatic Cancer               <ul style="list-style-type: none"> <li>■ Subjects with metastatic/stage IV lung cancer</li> <li>■ Subjects with locally advanced/stage III lung cancer</li> </ul> </li> </ul> </li> <li>■ Subjects with EGFR Positive Lung Cancer</li> <li>■ <b>Subjects with gene variants</b> <ul style="list-style-type: none"> <li>■ EGFR_HUMAN_rs121434569(T)</li> <li>■ MET_HUMAN_Amplification</li> </ul> </li> </ul>		
Change History			
Sources			

\*Depending on your type of subscription.

To find out what's included in your subscription, contact your Clarivate account manager or [LS Product Support](#)